{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:44:40Z","timestamp":1777866280120,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017051","name":"Seoul National University College of Medicine","doi-asserted-by":"publisher","award":["800\\u201320240487"],"award-info":[{"award-number":["800\\u201320240487"]}],"id":[{"id":"10.13039\/100017051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HV22C0192"],"award-info":[{"award-number":["HV22C0192"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["NRF-2015R1A6A1A03032236"],"award-info":[{"award-number":["NRF-2015R1A6A1A03032236"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.vaccine.2025.127032","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T18:32:00Z","timestamp":1742409120000},"page":"127032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Immunogenicity and efficacy in mice of two adjuvant formulations based on the C -and N-terminus of merozoite surface protein 1 of Plasmodium yoelii"],"prefix":"10.1016","volume":"55","author":[{"given":"Su-Yeon","family":"Yun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minh-Ngoc","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyelee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gum-Ju","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Hui","family":"Eom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vui Thi","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seon-Ju","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127032_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2025.101073","article-title":"WHO world malaria report 2024","author":"Venkatesan","year":"2025","journal-title":"Lancet Microbe"},{"issue":"9988","key":"10.1016\/j.vaccine.2025.127032_bb0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","author":"Tinto","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127032_bb0015","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","article-title":"Immunogenicity of the RTS,S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial","volume":"15","author":"White","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127032_bb0020","doi-asserted-by":"crossref","DOI":"10.1038\/srep46621","article-title":"Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine","volume":"7","author":"Collins","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.127032_bb0025","first-page":"618","article-title":"Monoclonal antibodies show promise for malaria prevention","volume":"S23","author":"Willyard","year":"2023","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127032_bb0030","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/14760584.2017.1341317","article-title":"Blood-stage malaria vaccines: post-genome strategies for the identification of novel vaccine candidates","volume":"16","author":"Ntege","year":"2017","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127032_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/biom14010100","article-title":"The need for novel asexual blood-stage malaria vaccine candidates for plasmodium falciparum","volume":"14","author":"Takashima","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.vaccine.2025.127032_bb0040","series-title":"WHO review of malaria vaccine clinical development","author":"WHO","year":"2024"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127032_bb0045","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1074\/mcp.M600035-MCP200","article-title":"Identification and stoichiometry of glycosylphosphatidylinositol-anchored membrane proteins of the human malaria parasite plasmodium falciparum","volume":"5","author":"Gilson","year":"2006","journal-title":"Mol Cell Proteomics"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127032_bb0050","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/femsre\/fuw001","article-title":"Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria","volume":"40","author":"Beeson","year":"2016","journal-title":"FEMS Microbiol Rev"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127032_bb0055","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1128\/IAI.00866-13","article-title":"Sequential processing of merozoite surface proteins during and after erythrocyte invasion by plasmodium falciparum","volume":"82","author":"Boyle","year":"2014","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127032_bb0060","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41541-020-0160-2","article-title":"Immunization with full-length plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial","volume":"5","author":"Blank","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127032_bb0065","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41541-023-00701-2","article-title":"Multifunctional IgG\/IgM antibodies and cellular cytotoxicity are elicited by the full-length MSP1 SumayaVac-1 malaria vaccine","volume":"8","author":"Rosenkranz","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127032_bb0070","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1128\/IAI.66.8.3925-3930.1998","article-title":"Passive immunization with antibodies against three distinct epitopes on plasmodium yoelii merozoite surface protein 1 suppresses parasitemia","volume":"66","author":"Spencer Valero","year":"1998","journal-title":"Infect Immun"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127032_bb0075","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1084\/jem.193.12.1403","article-title":"Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria","volume":"193","author":"O\u2019Donnell","year":"2001","journal-title":"J Exp Med"},{"issue":"29\u201330","key":"10.1016\/j.vaccine.2025.127032_bb0080","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1016\/j.vaccine.2004.07.023","article-title":"Pre-clinical evaluation of the malaria vaccine candidate P. Falciparum MSP1(42) formulated with novel adjuvants or with alum","volume":"22","author":"Pichyangkul","year":"2004","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2025.127032_bb0085","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1016\/j.vaccine.2005.11.028","article-title":"Phase I safety and immunogenicity trial of FMP1\/AS02A, a plasmodium falciparum MSP-1 asexual blood stage vaccine","volume":"24","author":"Ockenhouse","year":"2006","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127032_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pctr.0010032","article-title":"Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children","volume":"1","author":"Withers","year":"2006","journal-title":"PLoS Clin Trials"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127032_bb0095","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.vaccine.2005.11.037","article-title":"Phase 1 randomized double-blind safety and immunogenicity trial of plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya","volume":"25","author":"Stoute","year":"2007","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127032_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pctr.0010034","article-title":"Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial","volume":"1","author":"Thera","year":"2006","journal-title":"PLoS Clin Trials"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127032_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004708","article-title":"Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya","volume":"4","author":"Ogutu","year":"2009","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127032_bb0110","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1016\/j.vaccine.2024.03.072","article-title":"A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naive adults","volume":"42","author":"Cummings","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127032_bb0115","series-title":"Saponins as vaccine adjuvants","first-page":"1","volume":"13","author":"Kensil CRJCritdcs.","year":"1996"},{"key":"10.1016\/j.vaccine.2025.127032_bb0120","series-title":"Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles","first-page":"69","volume":"3","author":"O\u2019Hagan","year":"1997"},{"key":"10.1016\/j.vaccine.2025.127032_bb0125","series-title":"Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines","first-page":"103","volume":"19","author":"Baldridge","year":"1999"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127032_bb0130","first-page":"870","article-title":"CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen","volume":"160","author":"Davis","year":"1998"},{"key":"10.1016\/j.vaccine.2025.127032_bb0135","series-title":"Immune responses to ISCOM\u00ae formulations in animal and primate models","first-page":"2661","volume":"19","author":"Sj\u00f6lander","year":"2001"},{"key":"10.1016\/j.vaccine.2025.127032_bb0140","series-title":"Efficacy of RTS, S\/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial","first-page":"1927","volume":"358","author":"Bojang","year":"2001"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127032_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024782","article-title":"T cell epitope regions of the P. Falciparum MSP1-33 critically influence immune responses and in vitro efficacy of MSP1-42 vaccines","volume":"6","author":"Pusic","year":"2011","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127032_bb0150","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00155-17","article-title":"Merozoite surface protein 1 from plasmodium falciparum is a major target of opsonizing antibodies in individuals with acquired immunity against malaria","volume":"24","author":"Jaschke","year":"2017","journal-title":"Clin Vaccine Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127032_bb0155","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/IAI.74.5.2726-2733.2006","article-title":"A reduced risk of infection with plasmodium vivax and clinical protection against malaria are associated with antibodies against the N terminus but not the C terminus of merozoite surface protein 1","volume":"74","author":"Nogueira","year":"2006","journal-title":"Infect Immun"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127032_bb0160","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.1128\/IAI.72.11.6492-6502.2004","article-title":"Antibodies to the N-terminal block 2 of plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria","volume":"72","author":"Cavanagh","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.127032_bb0165","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/1475-2875-12-294","article-title":"High levels of IgG3 anti ICB2-5 in plasmodium vivax-infected individuals who did not develop symptoms","volume":"12","author":"Versiani","year":"2013","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2025.127032_bb0170","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/965841","article-title":"N-terminal Plasmodium vivax merozoite surface protein-1, a potential subunit for malaria vivax vaccine","volume":"2013","author":"Versiani","year":"2013","journal-title":"Clin Dev Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127032_bb0175","article-title":"Advancements in vaccine adjuvants: the journey from alum to Nano formulations","volume":"11","author":"Moni","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127032_bb0180","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.vaccine.2025.127032_bb0185","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","article-title":"CpG motifs in bacterial DNA and their immune effects","volume":"20","author":"Krieg","year":"2002","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127032_bb0190","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/icb.2011.98","article-title":"Arginase-dependent suppression by CpG-ODN plus IFA-induced splenic myeloid CD11b(+)Gr1(+) cells","volume":"90","author":"Ranocchia","year":"2012","journal-title":"Immunol Cell Biol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127032_bb0195","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1128\/IAI.72.2.949-957.2004","article-title":"CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine","volume":"72","author":"Kumar","year":"2004","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127032_bb0200","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1128\/CVI.00397-06","article-title":"Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of plasmodium yoelii merozoite surface protein 1 in mice","volume":"14","author":"Jeamwattanalert","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2025.127032_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.exppara.2020.107944","article-title":"Measuring of IgG2c isotype instead of IgG2a in immunized C57BL\/6 mice with plasmodium vivax TRAP as a subunit vaccine candidate in order to correct interpretation of Th1 versus Th2 immune response","volume":"216","author":"Nazeri","year":"2020","journal-title":"Exp Parasitol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127032_bb0210","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/14760584.2023.2295430","article-title":"Plasmodium falciparum merozoite surface protein 1 as asexual blood stage malaria vaccine candidate","volume":"23","author":"Thomson-Luque","year":"2024","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127032_bb0215","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.4049\/jimmunol.157.3.1176","article-title":"Genetic regulation of protective immune response in congenic strains of mice vaccinated with a subunit malaria vaccine","volume":"157","author":"Tian","year":"1996","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127032_bb0220","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127032_bb0225","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4049\/jimmunol.155.1.236","article-title":"Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria","volume":"155","author":"Daly","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2025.127032_bb0230","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/bs.mie.2019.05.020","article-title":"CFSE dilution to study human T and NK cell proliferation in vitro","volume":"631","author":"Terren","year":"2020","journal-title":"Methods Enzymol"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127032_bb0235","article-title":"Plasmodium falciparum Malaria Vaccines and Vaccine Adjuvants","volume":"9","author":"Bonam","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127032_bb0240","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1128\/IAI.68.4.2215-2223.2000","article-title":"Immunogenicity and efficacy in aotus monkeys of four recombinant plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1","volume":"68","author":"Kumar","year":"2000","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127032_bb0245","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.biologicals.2009.02.019","article-title":"A novel vaccine adjuvant for recombinant flu antigens","volume":"37","author":"Chang","year":"2009","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2025.127032_bb0250","series-title":"CpG ODN1826 as a promising mucin1-maltose-binding protein vaccine adjuvant induced DC maturation and enhanced antitumor immunity","first-page":"920","volume":"19","author":"Jie","year":"2018"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127032_bb0255","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1128\/IAI.70.2.692-701.2002","article-title":"Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model","volume":"70","author":"Near","year":"2002","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127032_bb0260","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004709","article-title":"Peptide emulsions in incomplete Freund\u2019s adjuvant create effective nurseries promoting egress of systemic CD4(+) and CD8(+) T cells for immunotherapy of cancer","volume":"10","author":"Melssen","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"21\u221222","key":"10.1016\/j.vaccine.2025.127032_bb0265","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1016\/S0264-410X(03)00132-4","volume":"21","author":"Hirunpetcharat","year":"2003","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127032_bb0270","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.4049\/jimmunol.159.7.3400","volume":"159","author":"Hirunpetcharat","year":"1997","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127032_bb0275","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1189\/jlb.0604341","article-title":"BALB\/c mice have more CD4+CD25+ T regulatory cells and show greater susceptibility to suppression of their CD4+CD25- responder T cells than C57BL\/6 mice","volume":"78","author":"Chen","year":"2005","journal-title":"J Leukoc Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127032_bb0280","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0166-6851(01)00329-2","article-title":"Interaction between two domains of the P. Yoelii MSP-1 protein detected using the yeast two-hybrid system","volume":"117","author":"Daly","year":"2001","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.vaccine.2025.127032_bb0285","series-title":"Genetic diversity in plasmodium falciparum merozoite surface protein 1 and 2 coding genes and its implications in malaria epidemiology: A review of published studies from 1997\u20132007","author":"Kiwanuka","year":"2009"},{"key":"10.1016\/j.vaccine.2025.127032_bb0290","series-title":"A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses","first-page":"689","volume":"6","author":"Conway","year":"2000"},{"key":"10.1016\/j.vaccine.2025.127032_bb0295","series-title":"A prospective study of the association between the human humoral immune response to Plasmodium falciparum blood stage antigen gp190 and control of malarial infections","first-page":"40","volume":"61","author":"Tolle","year":"1993"},{"key":"10.1016\/j.vaccine.2025.127032_bb0300","series-title":"Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with aluminium-adsorbed and fluid DT-vaccines","first-page":"669","volume":"13","author":"Mark","year":"1995"},{"key":"10.1016\/j.vaccine.2025.127032_bb0305","series-title":"Summary: adjuvants\/clinical trials working group","first-page":"1427","volume":"8","author":"Alving","year":"1992"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25003299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25003299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:21:56Z","timestamp":1777537316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25003299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":61,"alternative-id":["S0264410X25003299"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127032","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and efficacy in mice of two adjuvant formulations based on the C -and N-terminus of merozoite surface protein 1 of Plasmodium yoelii","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127032"}}